Clinical trials: Prostate-Specific Antigen
Prostate Cancer
Phase 1 of EC1169 In Patients With Recurrent MCRPC
The purpose of this study is to determine the safety of EC1169 and the best dose to use in humans in future studies. This study will also determine how EC1169 is distributed, broken down, passed and absorbed through your body and…
- Trial name
- NCT02202447
- Testing
- EC1169, EC0652
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Endocyte
Prostatic Neoplasm, Prostate Cancer
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
The main purpose of this study was to determine whether ADT started before or after sipuleucel-T led to a better immune system response.
- Conditions
- Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma
- Trial name
- NCT01431391
- Testing
- sipuleucel-T, leuprolide acetate
- Where
- 14 sites in United States
- Volunteers
- 68 people
- Sponsor
- Dendreon
Metastatic Prostate Cancer
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
This is a phase 1 study to assess the safety and tolerability of ARX517 as monotherapy or combination therapy in adult subjects with metastatic prostate cancer (mPC).
- Trial name
- ARX517 (NCT04662580)
- Testing
- ARX517, Apalutamide, Abiraterone acetate
- Where
- 12 sites in United States
- Volunteers
- 183 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms
Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer
Primary Objective: To compare the continuation of treatment with docetaxel versus switching to cabazitaxel regarding the time to PSA (Prostatic Specific Antigen) progression (TTP-PSA), in patients with Castration-Resistant…
- Trial name
- SWITCH (NCT01576029)
- Testing
- CABAZITAXEL (XRP6258), DOCETAXEL (XRP6976)
- Where
- 8 sites in Brazil
- Volunteers
- 2 people
- Sponsor
- Sanofi
Prostatic Neoplasms
A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-80038114 in Part 1 (dose escalation) and to determine the safety at the RP2D(s) in Part 2 (dose expansion).
- Trial name
- NCT05441501
- Testing
- JNJ-80038114
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Janssen Research & Development, LLC
Castration-resistant Prostate Cancer
A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-RAD402, a Radiolabeled Anti-KLK3 Monoclonal Antibody Targeting Free Prostate-Specific Antigen, in…
- Trial name
- RAD402 (NCT07259213)
- Testing
- 161Tb RAD402
- Where
- 2 sites in Australia
- Volunteers
- 73 people
- Sponsor
- Radiopharm Theranostics, Ltd
Prostatic Neoplasms
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the…
- Trial name
- NCT07082920
- Testing
- JNJ-78278343, JNJ-95298177, JNJ-87189401
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 140 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Researchers are looking for a better way to treat participants who have metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- PAnTHA (NCT06217822)
- Testing
- 225Ac-PSMA-Trillium (BAY3563254)
- Where
- 35 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Advanced and/or Metastatic Solid Tumours
Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.
FIH, Phase 1, open-label, multi centre study of CB307, a trispecific Humabody® T-cell enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours to assess safety and tolerability to determine MTD and preliminary…
- Trial name
- POTENTIA (NCT04839991)
- Testing
- CB307
- Where
- 20 sites in United States, Netherlands and 2 more
- Volunteers
- 70 people
- Sponsor
- Crescendo Biologics Ltd.
Prostate Cancer
ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)
This study is being carried out to see if ZD4054 (Zibotentan) is effective in treating prostate cancer and spread of cancer to the bone, and if so, how it compares with placebo (sugar pill).
- Trial name
- NCT00090363
- Testing
- ZD4054 15 mg, ZD4054 10 mg
- Where
- 60 sites in United States, Australia and 12 more
- Volunteers
- 447 people
- Sponsor
- AstraZeneca
Prostate Cancer
Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer
This is a multi-center, open-label, dose finding study of CV787 adenovirus in patients with hormone refractory metastatic prostate cancer.
- Trial name
- NCT00116155
- Testing
- CV787 (CG7870)
- Sponsor
- Cell Genesys
Prostate Cancer, Prostate Cancer Screening
Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer
This ambispective observational cohort study will evaluate the clinical performance of the ClarityDX Prostate blood test in men with a prostate-specific antigen (PSA) level of 3 ng/mL or higher who are undergoing prostate biopsy…
- Conditions
- Prostate Cancer, Prostate Cancer Screening, Performance Assessment of Novel Test
- Trial name
- APCaRI-05 (NCT03957252)
- Where
- 3 sites in United States, Canada
- Volunteers
- 2,800 people
- Sponsor
- Nanostics
Metastatic Neuroendocrine Prostate Cancer
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
The purpose of this study is to evaluate the change in the expression of treatment targets on the surface of tumor cells (Prostate Specific Membrane Antigen (PSMA), Somatostatin Receptor 2 (SSTR2), and Gastrin Releasing Peptide…
- Trial name
- NCT06379217
- Testing
- [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB
- Where
- 9 sites in United States, France and 3 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Unresectable, Metastatic
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers.
- Trial name
- SELECT-2CAR (NCT07523529)
- Testing
- Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Beijing Biotech
Metastatic Castration-Resistant Prostatic Cancer
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with…
- Trial name
- NCT07258407
- Testing
- TD001
- Where
- 7 sites in United States, Australia and 3 more
- Volunteers
- 180 people
- Sponsor
- T.O.A.D. Oncology SA
Advanced Prostate Cancer
Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide
Prospective, non-comparative, non-interventional, observational study to collect and analyse real life environment data on advanced prostate cancer patients receiving combination treatment of medical or surgical castration and…
- Trial name
- NCT00871585
- Where
- 15 sites in Croatia
- Volunteers
- 340 people
- Sponsor
- AstraZeneca
Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
The purpose of this study was to evaluate the impact of concurrent versus sequential administration of abiraterone acetate plus prednisone on the ability to manufacture sipuleucel-T (by assessing sipuleucel-T product parameters)…
- Conditions
- Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT01487863
- Testing
- sipuleucel-T, abiraterone acetate
- Where
- 21 sites in United States
- Volunteers
- 69 people
- Sponsor
- Dendreon
Prostate Cancer
A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers
This is a single-blind, randomized, cross-over design. Patients with metastatic prostate adenocarcinoma; newly diagnosed, high-risk patients with prostate adenocarcinoma; and healthy subjects will be administered a single…
- Trial name
- NCT01261754
- Testing
- 99mTc MIP 1404, 99mTc MIP 1405
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Prostate Cancer
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
The purpose of this study is to assess the efficacy, tolerability, safety, pharmacokinetic (PK) and dosimetry of 177Lu-PSMA-617, in participants with progressive prostate-specific membrane antigen (PSMA)-positive metastatic…
- Trial name
- NCT05114746
- Testing
- 177Lu-PSMA-617, 68Ga-PSMA-11, Best supportive/best standard of care
- Where
- 8 sites in Japan
- Volunteers
- 94 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Study of CEP-701 in Treatment of Prostate Cancer
The purpose of this study is to determine the proportion of patients with a serological prostate specific antigen (PSA) by day 85.
- Trial name
- NCT00081601
- Testing
- CEP-701
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cephalon